Key result
Despite evidence that glycoprotein IIb/IIIa inhibitors reduce morbidity and mortality in acute coronary syndromes and PCI, registry data indicate substantial underuse in eligible patients.
Why the study?
Does the use of glycoprotein IIb/IIIa inhibitors reduce morbidity and mortality in patients with acute coronary syndromes and those undergoing PCI?
Does the use of glycoprotein IIb/IIIa inhibitors reduce morbidity and mortality in patients with acute coronary syndromes and those undergoing PCI?
Glycoprotein IIb/IIIa inhibitors are underutilized in eligible ACS and PCI patients despite guideline recommendations, likely due to controversies over their modest effect and optimal combination therapies.
Answers are grounded in this paper and cite their sources.
Registry data show persistent underuse of glycoprotein IIb/IIIa inhibitors in eligible ACS/PCI patients; supports consensus benefit but leaves adoption barriers open.
The use of glycoprotein IIb/IIIa inhibitors reduces morbidity and mortality in patients with acute coronary syndromes and patients undergoing percutaneous coronary intervention. Despite the sound body of evidence that supports the use of these agents, registry data indicate that there is substantial underuse in eligible patients. This may be due to their modest treatment effect, controversy over the significance of reductions in recurrent myocardial infarction, or confusion over appropriate combinations of antiplatelet and antithrombin agents. The challenge for clinicians is to identify patients that receive the most benefit from the use of glycoprotein IIb/IIIa inhibitors. Until the results of ongoing trials become available, the American College of Cardiology/American Heart Association guidelines provide reasonable recommendations on the use of these agents in clinical practice.
No takes yet. Share an insight, caveat, or question.
Sunil V. Rao (2003) conducted a review in Acute coronary syndromes and percutaneous coronary intervention. Glycoprotein IIb/IIIa inhibitors was evaluated. Despite evidence that glycoprotein IIb/IIIa inhibitors reduce morbidity and mortality in acute coronary syndromes and PCI, registry data indicate substantial underuse in eligible patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: